BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

FDMT upcoming catalysts

4D Molecular Therapeutics: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 3 readout(s) and 0 FDA event(s). Subscribe to FDMT (.ics).

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-06 est.P1/P24D Molecular Therapeutics FDMTNCT05629559 4D-310 in Adults With Fabry Disease and Cardiac InvolvementFabry Diseaserecruiting18
2026-06 est.P1/P24D Molecular Therapeutics FDMTNCT04517149 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)X-Linked Retinitis Pigmentosaactive not recruiting21
2026-01 est.P1/P24D Molecular Therapeutics FDMTNCT04519749 An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry DiseaseFabry Diseaseactive not recruiting18

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.